SETTING: The Central African Republic (CAR) is a country with a high burden of tuberculosis (TB). Although its national tuberculosis programme is effective, there is no continuous surveillance system for anti-tuberculosis drug resistance in place. OBJECTIVE: To establish base-line anti-tuberculosis drug resistance data to allow for future monitoring of trends and evolutions. More specifically, we aimed at investigating primary anti-tuberculosis drugs in Bangui and Bimbo, two cities of CAR. METHOD: A total of 225 Mycobacterium tuberculosis isolates were tested for susceptibility to the anti-tuberculosis drugs commonly used in the country (isoniazid [INH, H], rifampicin [R], streptomycin [SM, S] and ethambutol [EMB, E]). Human immunodeficiency virus co-infection was recorded. RESULTS: Overall primary drug resistance was found to be 14.7% (33/225). The highest rate of primary resistance was for INH (9.3%), followed by SM (8.4%), and EMB (2.2%). The multidrug resistance rate was 0.4%. CONCLUSION: Our study indicates that primary drug resistance levels in urban settings of CAR are similar to or lower than in other African cities, and that the spread of multidrug-resistant TB in this population is limited. Extended nationwide monitoring of drug resistance remains important, especially in view of the planned introduction of a new treatment regimen (2HRZE/4HR [Z = pyrazinamide]).
SETTING: The Central African Republic (CAR) is a country with a high burden of tuberculosis (TB). Although its national tuberculosis programme is effective, there is no continuous surveillance system for anti-tuberculosis drug resistance in place. OBJECTIVE: To establish base-line anti-tuberculosis drug resistance data to allow for future monitoring of trends and evolutions. More specifically, we aimed at investigating primary anti-tuberculosis drugs in Bangui and Bimbo, two cities of CAR. METHOD: A total of 225 Mycobacterium tuberculosis isolates were tested for susceptibility to the anti-tuberculosis drugs commonly used in the country (isoniazid [INH, H], rifampicin [R], streptomycin [SM, S] and ethambutol [EMB, E]). Human immunodeficiency virus co-infection was recorded. RESULTS: Overall primary drug resistance was found to be 14.7% (33/225). The highest rate of primary resistance was for INH (9.3%), followed by SM (8.4%), and EMB (2.2%). The multidrug resistance rate was 0.4%. CONCLUSION: Our study indicates that primary drug resistance levels in urban settings of CAR are similar to or lower than in other African cities, and that the spread of multidrug-resistant TB in this population is limited. Extended nationwide monitoring of drug resistance remains important, especially in view of the planned introduction of a new treatment regimen (2HRZE/4HR [Z = pyrazinamide]).
Authors: Deus Lukoye; Willy Ssengooba; Kenneth Musisi; George W Kasule; Frank G J Cobelens; Moses Joloba; Gabriela B Gomez Journal: BMC Public Health Date: 2015-03-25 Impact factor: 3.295
Authors: Baba Maiyaki Musa; Aishatu L Adamu; Najibah A Galadanci; Bashir Zubayr; Chisom N Odoh; Muktar H Aliyu Journal: PLoS One Date: 2017-09-25 Impact factor: 3.240
Authors: Alain Farra; Alexandre Manirakiza; Brice Martial Yambiyo; Germain Zandanga; Boris Lokoti; Alain Berlioz-Arthaud; Gilles Ngaya; Georges Hermana; Louis Médard Ourandji; Albert Ignaleamoko; Aristide Désiré Komangoya-Nzonzo; Jean Pierre Simelo; Jean de Dieu Iragena Journal: Open Forum Infect Dis Date: 2019-02-22 Impact factor: 3.835